RSV Townhall to Discuss Nirsevimab
Come learn about the newly approved monoclonal antibody, nirsevimab (Beyfortus), to prevent RSV in neonates and young infants at a townhall hosted by the Philadelphia Immunization Program.
The townhall will take place over Zoom on Tuesday August 29 at 12pm.
Nirsevimab will be available to order through the VFC Program this fall. Prepare your practice for ordering and administration of the product at next week’s townhall.